source
- Mid-dose petrelintide shows strongest weight loss in phase-2 trial, paving way for pivotal studyRoche and Zealand Pharma released new phase-2 data for petrelintide, an amylin analog being developed for obesity treatment. In the Zupreme 1 trial, the 5 mg dose achieved the greatest mean weight…
- Bristol Myers revises Phase 3 fibrosis trial after liver safety events, including a deathBristol Myers Squibb announced a change to its late-stage Phase 3 "Aloft" trial of the experimental pulmonary fibrosis drug admilparant. The amendment adds closer monitoring for liver-related adve…BioPharma Dive · 1mo agoNegative readoutNegative